Womed

admin1742025-09-18 11:07:42

About Womed

Womed is a biotechnology research company headquartered in Montpellier, Occitanie, France. Founded in 2018, it is privately owned and focuses on developing innovative, safe, and effective treatments for women with uterine pathologies such as infertility, uterine bleeding, and endometriosis. Its flagship product, Womed Leaf®, is the first medical device approved by the U.S. FDA for the treatment of Asherman syndrome (intrauterine adhesions) and has also been launched in Europe. To date, the company has raised €6 million to support its product development and commercialization.

Core Business & Key Technologies

Womed’s core business addresses women’s uterine health. Its flagship innovation, Womed Leaf®, is a soft, flexible film made from proprietary polymer technology. Inserted into the uterus following procedures like hysteroscopic surgery, it expands to prevent uterine walls from adhering for one week before being naturally and painlessly expelled. Clinically validated in the PREG2 trial with 160 patients, Womed Leaf® is the first physical barrier specifically designed to prevent intrauterine adhesion formation. Beyond Womed Leaf®, the company is advancing new intrauterine solutions, including a low-dose fibroid treatment to reduce abnormal bleeding, a novel intrauterine drug delivery system for endometriosis, and a rapid-response treatment for acute uterine bleeding.

Market Position & Flagship Products

Womed Leaf® is a pioneering device in intrauterine adhesion prevention, already recognized as a breakthrough in fertility preservation for women undergoing procedures such as dilation and curettage or fibroid removal. It is the first intrauterine adhesion barrier film launched in Europe and has been awarded for its innovation. With FDA approval and European market entry, Womed Leaf® is positioned to become the new gold standard for intrauterine adhesion management and fertility support.